SLC5A2 and heart failure: The SGLT-2 inhibitors(dapagliflozin or empagliflozin) have become the first-line treatment with ClassI recommendations for both HFmrEF and heart failure with preserved ejectionfraction (HFpEF), as well as for reducing hospitalization or cardiovascular deathdue to HF.